SDG 3. GOOD HEALTH & WELL-BEING Exscientia

Exscientia Announces Second Molecule Created Using AI From Sumitomo Dainippon Pharma Collaboration to Enter Phase 1 Clinical Trial

OXFORD, England–(BUSINESS WIRE)–Exscientia Ltd. (Headquarters: Oxford, UK; CEO: Andrew Hopkins) is pleased to acknowledge that Sumitomo Dainippon Pharma Co., Ltd. (Head office: Osaka, Japan, Representative Director, President and CEO: Hiroshi Nomura) has announced that they will initiate a Phase 1 clinical study of DSP-0038 in the United States for the treatment of Alzheimer’s disease psychosis. DSP-0038 is the third molecule created using Exscientia’s Artificial Intelligence (AI) technologie






Read more on Business Wire Technology News

You may also like

Leave a reply

Your email address will not be published. Required fields are marked *